[go: up one dir, main page]

CY1111498T1 - MINIMIZING THE EXPERIENCE CONCERNING OXYBUTININE TREATMENT - Google Patents

MINIMIZING THE EXPERIENCE CONCERNING OXYBUTININE TREATMENT

Info

Publication number
CY1111498T1
CY1111498T1 CY20111100189T CY111100189T CY1111498T1 CY 1111498 T1 CY1111498 T1 CY 1111498T1 CY 20111100189 T CY20111100189 T CY 20111100189T CY 111100189 T CY111100189 T CY 111100189T CY 1111498 T1 CY1111498 T1 CY 1111498T1
Authority
CY
Cyprus
Prior art keywords
oxybutinine
minimizing
treatment
oxybutynin
experience concerning
Prior art date
Application number
CY20111100189T
Other languages
Greek (el)
Inventor
Steven W Sanders
Charles D Ebert
Original Assignee
Watson Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24234699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111498(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Watson Pharmaceuticals, Inc. filed Critical Watson Pharmaceuticals, Inc.
Publication of CY1111498T1 publication Critical patent/CY1111498T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition that minimises an adverse drug experience associated with oxybutynin therapy comprises oxybutynin, wherein the composition in use provides a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1.
CY20111100189T 2000-04-26 2011-02-16 MINIMIZING THE EXPERIENCE CONCERNING OXYBUTININE TREATMENT CY1111498T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55971100A 2000-04-26 2000-04-26
EP01927318A EP1280486B1 (en) 2000-04-26 2001-04-24 Minimizing adverse experience associated with oxybutynin therapy

Publications (1)

Publication Number Publication Date
CY1111498T1 true CY1111498T1 (en) 2015-08-05

Family

ID=24234699

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100189T CY1111498T1 (en) 2000-04-26 2011-02-16 MINIMIZING THE EXPERIENCE CONCERNING OXYBUTININE TREATMENT

Country Status (16)

Country Link
US (6) US6743441B2 (en)
EP (3) EP2322170A1 (en)
JP (3) JP2003531157A (en)
CN (4) CN102327253A (en)
AT (1) ATE488233T1 (en)
AU (2) AU2001253782B2 (en)
BR (1) BR0110381A (en)
CA (1) CA2406064C (en)
CY (1) CY1111498T1 (en)
DE (1) DE60143477D1 (en)
DK (1) DK1280486T3 (en)
ES (1) ES2357699T3 (en)
HK (1) HK1052287A1 (en)
MX (2) MXPA02010542A (en)
PT (1) PT1280486E (en)
WO (1) WO2001080796A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR018321A1 (en) * 1998-03-26 2001-11-14 Alza Corp A DOSAGE FORM OF PROLONGED LIBERATION THAT INCLUDES OXIBUTININE AND THE USES OF OXIBUTININE AND THE DOSAGE FORM OF PROLONGED LIBERATION.
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
DK1280486T3 (en) * 2000-04-26 2011-02-14 Watson Pharmaceuticals Inc Minimizing side effect associated with oxybutinin therapy
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
JP2004505931A (en) * 2000-08-03 2004-02-26 アンタレス　ファルマ　アイピーエル　アクチェンゲゼルシャフト Novel compositions for transdermal and / or transmucosal administration of active compounds ensuring adequate therapeutic levels
US8226972B2 (en) * 2001-12-20 2012-07-24 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
JP4354678B2 (en) * 2002-08-28 2009-10-28 久光製薬株式会社 Patch
AU2012216593B2 (en) * 2002-11-01 2014-09-25 Allergan Sales, Llc Compositions and methods for transdermal oxybutynin therapy
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
EP1578421A4 (en) * 2003-01-02 2009-04-22 Femmepharma Holding Co Inc Pharmaceutical preparations for treatments of diseases and disorders of the breast
DE10315878B4 (en) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Device for transdermal administration of fesoterodine and use
MXPA06003316A (en) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues.
TW200514582A (en) * 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
JP5097359B2 (en) 2006-05-09 2012-12-12 久光製薬株式会社 Donepezil transdermal preparation
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
EP2104489A2 (en) * 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
TWI630208B (en) 2008-12-08 2018-07-21 歐陸斯迪公司 Dihydroetorphine
US8920392B2 (en) * 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
EP2563123B1 (en) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US20140135392A1 (en) * 2012-11-13 2014-05-15 NeuRx Pharmaceuticals LLC Methods for the treatment of sialorrhea
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
WO2016112263A1 (en) 2015-01-09 2016-07-14 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
WO2017147147A1 (en) * 2016-02-23 2017-08-31 PixarBio Corporation Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same
EP3662905B1 (en) * 2017-08-01 2022-05-04 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147236A (en) * 1874-02-10 Improvement in devices for riveting the teeth of saws
NL124473C (en) * 1960-07-26
US5736577A (en) 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5028430A (en) 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5641504A (en) 1988-06-09 1997-06-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolinoleate
WO1990014833A1 (en) * 1989-06-07 1990-12-13 Bazzano Gail S Slow release vehicles for minimizing skin irritancy of topical compositions
US5922342A (en) 1990-10-01 1999-07-13 Pharmacia & Upjohn Company Lateral edge coated controlled release pharmaceutical compositions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5212199A (en) 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
PT100502A (en) 1991-05-20 1993-08-31 Alza Corp PHARMACEUTICAL COMPOSITIONS FOR INCREASING THE CAPACITY OF PERMEACAO IN THE SKIN USING GLYCEROL MONOLINOLEATE
AU670777B2 (en) 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
CA2132865C (en) * 1992-05-13 2003-12-02 Eun S. Lee Transdermal administration of oxybutynin
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
JP3277342B2 (en) 1992-09-02 2002-04-22 武田薬品工業株式会社 Manufacturing method of sustained release microcapsules
AU679794B2 (en) 1993-09-29 1997-07-10 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutynin
WO1995024172A1 (en) 1994-03-07 1995-09-14 Theratech, Inc. Drug-containing adhesive composite transdermal delivery device
US5441740A (en) * 1994-05-06 1995-08-15 Longevity Network. Ltd. Cosmetic composition containing alpha hydroxyacids, salicyclic acid, and enzyme mixture of bromelain and papain
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
EP0782861B1 (en) * 1994-10-05 2001-12-12 Hisamitsu Pharmaceutical Co., Inc. Drug compounding ingredients comprising n-substituted-o-toluidine derivative and percutaneously absorbable preparation
US5516808A (en) 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5532278A (en) 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5862555A (en) 1995-04-06 1999-01-26 Furuhashi; Masanobu System and method for manufacturing shoes using a wooden mold
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5912268A (en) 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5759583A (en) 1995-08-30 1998-06-02 Syntex (U.S.A.) Inc. Sustained release poly (lactic/glycolic) matrices
SK284136B6 (en) 1996-02-02 2004-09-08 Alza Corporation Implantable device for delivering leuprolide to a fluid medium
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
IT1283102B1 (en) * 1996-06-06 1998-04-07 Permatec Nv THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US5769683A (en) * 1997-02-10 1998-06-23 Park; Young-Ho Attachment for balloon tether
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US6479373B2 (en) * 1997-02-20 2002-11-12 Infineon Technologies Ag Method of structuring layers with a polysilicon layer and an overlying metal or metal silicide layer using a three step etching process with fluorine, chlorine, bromine containing gases
DE69816980T2 (en) 1997-03-31 2004-07-22 Alza Corp., Palo Alto IMPLANTABLE DIFFUSION DELIVERY SYSTEM
DE19882286T1 (en) * 1997-04-03 2000-04-27 Point Biomedical Corp Intravesical drug delivery systems
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CA2309688C (en) * 1997-11-10 2007-04-24 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
US5891888A (en) * 1998-01-14 1999-04-06 Strahl; Robert Charles Physical endurance drink
DE19812413C1 (en) 1998-03-20 1999-06-10 Sanol Arznei Schwarz Gmbh Transdermal therapeutic system for administration of oxybutynin
AR018321A1 (en) 1998-03-26 2001-11-14 Alza Corp A DOSAGE FORM OF PROLONGED LIBERATION THAT INCLUDES OXIBUTININE AND THE USES OF OXIBUTININE AND THE DOSAGE FORM OF PROLONGED LIBERATION.
US5986305A (en) * 1998-03-30 1999-11-16 Texas Instruments - Acer Incorporated Semiconductor device with an inverse-T gate lightly-doped drain structure
FR2779438B1 (en) 1998-06-03 2004-12-24 Jean Marc Aiache STABLE GEL, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
DK1280486T3 (en) * 2000-04-26 2011-02-14 Watson Pharmaceuticals Inc Minimizing side effect associated with oxybutinin therapy
US6682368B2 (en) * 2000-05-31 2004-01-27 Tyco Electronics Corporation Electrical connector assembly utilizing multiple ground planes
US6545046B2 (en) 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
US6662368B1 (en) * 2000-09-11 2003-12-09 Arris International, Inc. Variable spare circuit group size and quantity having multiple active circuits

Also Published As

Publication number Publication date
BR0110381A (en) 2003-12-30
JP2003531157A (en) 2003-10-21
CN1438861A (en) 2003-08-27
JP6253734B2 (en) 2017-12-27
JP2017008085A (en) 2017-01-12
US7081251B2 (en) 2006-07-25
CA2406064C (en) 2011-03-15
EP1280486A1 (en) 2003-02-05
CN102327253A (en) 2012-01-25
DK1280486T3 (en) 2011-02-14
US7081249B2 (en) 2006-07-25
WO2001080796A1 (en) 2001-11-01
EP1280486B1 (en) 2010-11-17
MXPA02010542A (en) 2003-10-14
MX342305B (en) 2016-09-23
AU2001253782B2 (en) 2006-06-29
US20040120996A1 (en) 2004-06-24
JP2013082720A (en) 2013-05-09
US20060078613A1 (en) 2006-04-13
EP2322170A1 (en) 2011-05-18
CN101843601A (en) 2010-09-29
US20050048106A1 (en) 2005-03-03
JP6077294B2 (en) 2017-02-08
DE60143477D1 (en) 2010-12-30
US20050048107A1 (en) 2005-03-03
US20020147236A1 (en) 2002-10-10
US20040259954A1 (en) 2004-12-23
AU5378201A (en) 2001-11-07
EP1280486A4 (en) 2006-03-29
US6743441B2 (en) 2004-06-01
US7081252B2 (en) 2006-07-25
US7087241B2 (en) 2006-08-08
CA2406064A1 (en) 2001-11-01
ES2357699T3 (en) 2011-04-28
CN101305994A (en) 2008-11-19
ATE488233T1 (en) 2010-12-15
US7081250B2 (en) 2006-07-25
PT1280486E (en) 2011-02-28
HK1052287A1 (en) 2003-09-11
EP1992342A1 (en) 2008-11-19

Similar Documents

Publication Publication Date Title
CY1111498T1 (en) MINIMIZING THE EXPERIENCE CONCERNING OXYBUTININE TREATMENT
MY134129A (en) Polymorphs of an epothilone analog
AR025428A1 (en) FORMS OF DELAYED TRAMADOL ADMINISTRATION THROUGH A COATING CONTAINING THE ACTIVE TRAMADOL SUBSTANCE IN THE FORM OF A TRAMADOL SACARINATE EVENTUALLY ASSOCIATED OTHER EXCIPIENTS
ATE486840T1 (en) MODIFIED FORMS OF PHARMACEUTICALLY ACTIVE AGENTS AND USES THEREOF
SV2004001556A (en) ACID PREPARATIONS OF INSULIN WITH IMPROVED STABILITY
NO20013469L (en) Procedures for glucagon suppression
CY1110547T1 (en) CONCENTRATED DROUGHT VOLUME PROTEIN PREPARATIONS
DE122011100049I1 (en) Stable pharmaceutical solution formulations for pressurized inhalers for the administration of metered doses.
EA200400481A1 (en) APPLICATION OF FLIBANSERIN FOR THE TREATMENT OF SEXUAL DISORDERS
DE69805001D1 (en) OSMOTIC PHARMACEUTICAL FORM WITH TWO COATINGS
DK1036058T3 (en) adamantane
EE200000378A (en) Adamantane derivatives
DE60019334D1 (en) ANTIVIRAL ARZNEI
DK1112060T3 (en) Dosage form using liquid formulation
ATE291908T1 (en) IBUPROFEN ACTIVE INGREDIENT PREPARATION
HUP0202592A2 (en) Transdermal delivery of lasofoxifene
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
ES2152315T3 (en) XAMONELINE TARTRATO.
SE0000303D0 (en) Novel compounds
SE9902742D0 (en) New pharmaceutical formultion
ITRM20000433A0 (en) USE OF FIBRATES FOR THE PREPARATION OF A MEDICINAL PRODUCT USEFUL IN THE TREATMENT OF CONGESTIVE HEART FAILURE.
RU2001109481A (en) Antianginal agent
PT95757A (en) PREPARATION PROCEDURE OF PHARMACEUTICAL COMPOSITIONS N-METHYL-2- (PYRIDYL-3) -TETRAHYDRO-4-CARBOTIOAMIDE-2-OXIDE-1
DK1399143T3 (en) The use of Acetyl L-carnitine in the manufacture of a medicament for the treatment of anhedonia
AR003117A1 (en) THE USE OF AMINOTETHRALINE DERIVATIVE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE THERAPY OF CARDIOVASCULAR DISEASES AND SUCH PHARMACEUTICAL COMPOSITIONS.